De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
IDEXX Laboratories Inkomsten in het verleden
Verleden criteriumcontroles 3/6
IDEXX Laboratories is de winst gegroeid met een gemiddeld jaarlijks percentage van 14%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 11.5%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 10.2% per jaar. Het rendement op eigen vermogen van IDEXX Laboratories is 53.5%, en het heeft een nettomarge van 22.3%.
Belangrijke informatie
14.0%
Groei van de winst
14.8%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 8.9% |
| Inkomstengroei | 10.2% |
| Rendement op eigen vermogen | 53.5% |
| Nettomarge | 22.3% |
| Volgende winstupdate | 31 Oct 2024 |
Recente prestatie-updates uit het verleden
Recent updates
We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18
A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Sep 05What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?
Aug 20IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital
Jul 02Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
May 06Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$474 Based On Its Intrinsic Value?
Apr 23Opbrengsten en kosten
Hoe IDEXX Laboratories geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 3,785 | 846 | 934 | 208 |
| 31 Mar 24 | 3,725 | 867 | 925 | 199 |
| 31 Dec 23 | 3,661 | 845 | 902 | 191 |
| 30 Sep 23 | 3,588 | 823 | 888 | 183 |
| 30 Jun 23 | 3,514 | 791 | 877 | 183 |
| 31 Mar 23 | 3,431 | 699 | 858 | 259 |
| 31 Dec 22 | 3,367 | 679 | 851 | 255 |
| 30 Sep 22 | 3,340 | 670 | 848 | 257 |
| 30 Jun 22 | 3,309 | 664 | 840 | 249 |
| 31 Mar 22 | 3,274 | 735 | 821 | 164 |
| 31 Dec 21 | 3,215 | 745 | 796 | 161 |
| 30 Sep 21 | 3,135 | 757 | 770 | 154 |
| 30 Jun 21 | 3,047 | 728 | 777 | 152 |
| 31 Mar 21 | 2,858 | 674 | 739 | 146 |
| 31 Dec 20 | 2,707 | 582 | 735 | 141 |
| 30 Sep 20 | 2,591 | 497 | 717 | 138 |
| 30 Jun 20 | 2,475 | 460 | 674 | 134 |
| 31 Mar 20 | 2,457 | 437 | 681 | 135 |
| 31 Dec 19 | 2,407 | 428 | 669 | 133 |
| 30 Sep 19 | 2,351 | 423 | 657 | 128 |
| 30 Jun 19 | 2,291 | 407 | 642 | 123 |
| 31 Mar 19 | 2,252 | 390 | 638 | 120 |
| 31 Dec 18 | 2,213 | 377 | 632 | 118 |
| 30 Sep 18 | 2,170 | 330 | 621 | 117 |
| 30 Jun 18 | 2,117 | 307 | 610 | 115 |
| 31 Mar 18 | 2,045 | 284 | 596 | 112 |
| 31 Dec 17 | 1,969 | 263 | 575 | 109 |
| 30 Sep 17 | 1,906 | 277 | 561 | 106 |
| 30 Jun 17 | 1,862 | 263 | 547 | 104 |
| 31 Mar 17 | 1,820 | 245 | 534 | 102 |
| 31 Dec 16 | 1,775 | 222 | 522 | 101 |
| 30 Sep 16 | 1,732 | 214 | 516 | 101 |
| 30 Jun 16 | 1,690 | 202 | 502 | 100 |
| 31 Mar 16 | 1,637 | 192 | 493 | 99 |
| 31 Dec 15 | 1,602 | 192 | 482 | 100 |
| 30 Sep 15 | 1,554 | 174 | 475 | 99 |
| 30 Jun 15 | 1,531 | 182 | 467 | 99 |
| 31 Mar 15 | 1,508 | 182 | 457 | 100 |
| 31 Dec 14 | 1,486 | 182 | 448 | 98 |
| 30 Sep 14 | 1,488 | 199 | 435 | 96 |
| 30 Jun 14 | 1,443 | 193 | 422 | 93 |
| 31 Mar 14 | 1,405 | 190 | 409 | 89 |
| 31 Dec 13 | 1,377 | 188 | 401 | 88 |
Kwaliteitswinsten: IDXX heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (22.3%) IDXX } zijn lager dan vorig jaar (22.5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van IDXX is de afgelopen 5 jaar met 14% per jaar gegroeid.
Versnelling van de groei: De winstgroei van IDXX over het afgelopen jaar ( 6.8% ) ligt onder het 5-jarig gemiddelde ( 14% per jaar).
Winst versus industrie: De winstgroei IDXX over het afgelopen jaar ( 6.8% ) overtrof de Medical Equipment -sector 7.9%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 53.5% ) van IDXX wordt als uitstekend beschouwd.